Tucson’s Senphonix Wins NSF Funding for Continuous-Vitals Wearable

By Kyle Macdonald, COO of Silicon Oasis

A Tucson medical-technology startup is using federal research funding to push a new patient-monitoring platform closer to commercial manufacturing.

Senphonix announced that it has received a Phase I Small Business Technology Transfer award from the National Science Foundation through America’s Seed Fund. The NSF award database lists $304,950 in funding for the project, with Senphonix serving as the lead organization and the University of Arizona participating as a research partner.

The company is developing SleeveSense, a wearable designed to continuously monitor vital signs over extended periods rather than relying only on periodic measurements. The Phase I work will focus on the wireless and radio-frequency engineering required to improve the platform and move it from prototype development toward a product that can be manufactured at scale.

That matters beyond a single device.

One of Arizona’s biggest opportunities in technology is converting the research capacity inside its universities into companies, products and intellectual property that stay and grow here. Federal programs such as STTR are an important part of that bridge because they allow startups to work directly with research institutions while advancing commercially relevant engineering.

Senphonix is a good example of how that pipeline can work in Southern Arizona: a local startup, University of Arizona technical expertise and federal non-dilutive funding aimed at getting a technology closer to market.

As Arizona works to build a broader technology economy, commercialization infrastructure will matter as much as research itself. The Silicon Oasis is strongest when ideas developed here become companies built here.

Articles of Reference:
https://www.prnewswire.com/news-releases/senphonix-receives-national-science-foundation-grant-to-advance-sleevesense-a-continuous-long-term-vitals-monitoring-platform-302874427.html
https://nsf.elsevierpure.com/en/projects/sttr-phase-i-a-new-class-of-injection-molded-biosymbiotic-devices/